Beatty 2005.

Methods	N=30 Randomized Open label Fup: 24 weeks w/o: reported
Participants	Eligibility:‐ VL>500 ART: 2PI+2NRTI+1NNRTI Baseline CD4 47 cells/mm3 Baseline VL 4.72 log copies/ml Baseline ART: 2PI+2NRTI+1NNRTI
Interventions	16 wks STI
Outcomes	STI arm: CD4 decline: 27 cells/mm3 VL rebound: +0.4log cop/ml Post ART resumption STI arm:‐ VL decline < 75 cop/ml in 36% participants Control arm continuous ART: VL decline <74 cop/ml in 53% participants
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear